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ABSTRACT The beneficial effects of estrogens on the
cardiovascular system are associated with adverse effects
on reproductive tissues. On the basis of previous work
indicating a major role for estrogen receptor (ER)- in
maintaining cardiovascular health, we evaluated the tissue
selectivity of the ER-selective agonist propyl pyrazole
triol (PPT) compared with 17-estradiol (E2) in vivo. Four
weeks postovariectomy, equimolar doses of PPT and E2
were administered to rats in subcutaneous implants for
5 d. Both treatments restored rapid vasorelaxation of
aortic tissue to estrogenic agents and prevented coronary
hyperresponsiveness to angiotensin II in isolated heart
preparations. Accordingly, multiple endpoints of myocar-
dial ischemia-reperfusion injury exacerbated by ovariec-
tomy returned to baseline following treatment. These
protective effects were linked to increased in vivo levels of
endothelial progenitor cells (EPCs). Human EPC func-
tion was enhanced in vitro after PPT treatment. In sharp
contrast to E2, PPT treatment had no effect on uterine
weight and histomorphology except for vessel density,
and failed to up-regulate classic estrogen target genes.
Dissection of the effects on vascular reactivity and uterine
morphology was also observed following increased expo-
sure to PPT at a higher dose for longer time. These data
provide the first in vivo evidence for tissue-specific ER
activation. By conferring cardiovascular protection dis-
sected from unwanted uterotrophic effects, ER-selective
agonists may represent a potential safer alternative to natural
hormones.—Bolego, C., Rossoni, G., Fadini, G. P., Vegeto,
E., Pinna, C., Albiero, M., Boscaro, E., Agostini, C., Avogaro,
A., Gaion, R. M., Cignarella, A. Selective estrogen receptor-
agonist provides widespread heart and vascular protection
with enhanced endothelial progenitor cell mobilization in
the absence of uterotrophic action. FASEB J. 24, 2262–2272
(2010). www.fasebj.org
Key Words: tissue selectivity  ischemia-reperfusion  endothe-
lial function  pharmacology
The protective role of estrogen therapy in cardio-
vascular health has been challenged by the outcome of
large-scale clinical trials showing little or no benefit
associated with increased adverse effects. Because 17-
estradiol (E2) and other mammalian estrogens behave
as full and nonselective agonists on estrogen receptors
(ERs) (1), it is still debated which ER isoform mediates
the favorable effects of E2 on vascular function, inflam-
mation, atherosclerosis, hypertension, and stroke that
have emerged from experimental studies (2, 3).
Whereas it is well established that both ER and ER
are expressed to a variable extent in multiple circulat-
ing and resident vascular wall cell types (2), the two
isoforms govern distinct gene networks (4) and contrib-
ute to specific, redundant, or potentially opposing
functions in the heart and vasculature. To address the
respective role of ER and ER, genetic studies were
performed. Although initial studies indicated that both
ER and ER mediated the cardiovascular effects of E2
in a vascular injury model (5, 6), it is now clear that the
first ER-deficient model (ER-NeoKO) (7) was imper-
fect, as a transcriptional leakage gave rise to natural (46
kDa) and non-natural (55 kDa) AF-1-deficient ER
isoforms (8). Indeed, these vasculoprotective effects
persisted in this model but were abrogated in a com-
plete knockout ER/ (8–10). Current evidence in-
dicates that ER activity manifests mainly in preventing
the development of pulmonary hypertension (11, 12),
whereas most aspects of vascular, particularly endothe-
lial, function are mediated by ER activation (13–15).
The development of selective ligands for the ER
isoform in place of nonselective hormone agents, how-
ever, has been hampered by the fact that ER is also
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predominant in the uterus and appears to be respon-
sible for unwanted effects associated with estrogen and
selective estrogen receptor modulator (SERM) therapy
(16, 17). Highly selective ER agonists, such as propyl-
pyrazole-triol (PPT), have been developed; as expected,
this compound evokes responses in classical estrogen
target tissues, including uterine weight gain, but with
different potency from E2 (18). So far, few studies
tested the cardiovascular action of selective ER ago-
nists following in vivo administration (19–22). How-
ever, the tissue selectivity of these compounds was not
determined simultaneously in reproductive organs.
On the basis of differences in coactivator recruitment
and ER isoform selectivity compared with E2 (18, 23),
we hypothesized that in vivo administration of PPT
would allow dissecting the effects on cardiovascular
endpoints from uterotrophic response. To test this
hypothesis, we measured aortic vasorelaxation, protec-
tion from cardiac ischemia-reperfusion injury, and mo-
bilization of endothelial progenitor cells (EPCs), a
novel biomarker of cardiovascular health (24), in PPT-
and E2-treated ovariectomized rats. These experiments
revealed that PPT administration improved all these
aspects of cardiovascular function, without causing the
changes in uterine weight induced by an equimolar
dose of E2. To further investigate this phenomenon, we
assessed the differential effects of the two agents on
uterine histomorphology and profiled uterine gene
expression. Finally, we found that PPT could enhance
proliferation, clonogenic expansion, and adhesive ca-
pacity of cultured human EPCs, further suggesting that
ER-selective agonists may warrant testing as useful
adjuncts in improving cardiovascular health in post-
menopausal women.
MATERIALS AND METHODS
Animals
Female Sprague-Dawley rats (2 mo old; Charles River, Calco,
Italy), initial weight 200–225 g, were used. The animals were
housed in a conditioned environment (221°C, 555%
relative humidity, 12-h light/12-h dark cycle), with free access
to standard laboratory chow and tap water. The investigation
conforms to the Guide for the Care and Use of Laboratory Animals
published by the U.S. National Institutes of Health (Bethesda,
MD, USA; NIH Publication No. 85-23, revised 1996).
Experimental design
Experiments were conducted on 20 rats randomly divided
into 4 groups as follows: intact, ovariectomized (OVX), E2-
treated OVX, and PPT-treated OVX. Bilateral ovariectomy
was performed under ketamine (40 mg/kg i.p.) and xylazine
(20 mg/kg i.p.) anesthesia. Four weeks later, OVX animals
received a subcutaneous implant of 2 Silastic capsules con-
taining 25 l of vehicle (peanut oil) or E2 (5.87 g, 0.86 mM;
Sigma-Aldrich, St. Louis, MO, USA) or PPT (8.33 g, 0.86
mM; Tocris, Bristol, UK) for 5 d. Doses and duration of
treatment regimen were selected based on previous studies
(13, 25). Selected experiments were performed in OVX
animals after treatment with PPT or vehicle by implanting
larger capsules for 4 wk, as described elsewhere (26). At the
end of treatment, all rats were anesthetized by an intraperi-
toneal injection of thiopentone sodium (Pentothal, 60 mg/kg
body weight); blood was collected from the cava vein, the
uterus was removed and weighed, and the heart and thoracic
aorta were immediately harvested.
Isolated aorta experiments
Changes in vasomotor tone of aortic tissues in response to
acute E2 or PPT treatment were recorded in organ chambers
(13). The thoracic aorta was carefully removed, cleaned of fat
and connective tissue, and cut into 5- to 6-mm rings. Vessels
were suspended in 5-ml organ baths containing Krebs-Hensel-
heit solution (KHS) at 37°C, continuously bubbled with 95%
O2 and 5% CO2. KHS had the following composition (mM):
118 NaCl, 4.7 KCl, 1.2 KH2PO4, 1.1 MgSO4, 2.5 CaCl2, 25
NaHCO3, and 5.5 glucose; pH 7.4. The rings were connected
to isometric tension transducers (Fort 10; World Precision
Instruments, Sarasota, FL, USA) coupled with a digital re-
cording system (PowerLab 8SP; ADInstruments, Colorado
Springs, CO, USA). Vascular tissues were equilibrated for 30
min and contracted with 105 M noradrenalin (NA) to
develop a maximal response. Preparations were then washed
with fresh KHS, and the equilibration period was allowed to
continue for a further 30 min. Experiments were carried out
on tissues precontracted with NA to 60% of maximal contrac-
tion (EC6010
7 M). The endothelium was considered func-
tional because relaxation of precontracted vessels to 105 M
acetylcholine was 80%. Cumulative concentration-response
curves for E2 (nonselective ER agonist) and PPT (ER
agonist) were obtained over the concentration range 1013 to
107 M. To test vehicle effects, cumulative additions of
equivalent ethanol volumes were also performed. Ethanol
concentration never exceeded 0.01%, which however has
been shown to elicit MAPK and PI3K activation (27). Relax-
ant responses were expressed as percentage of residual NA-
induced contraction.
Indirect systolic blood pressure and heart rate
measurements in conscious rats
At the end of the experimental period, the animals were
weighed, and systolic blood pressure (SBP) was measured in
the conscious state by the tail-cuff method using apparatus
from Basile (mod 58500; Basile; Comerio, Italy). Before
tail-cuff blood pressure determination, animals were placed
into a warming cupboard (35°C) for 30 min. SBP values for
individual rats were obtained from the average of 4 consecu-
tive measurements and were considered valid only when these
readings did not differ by 5 mmHg. Heart rate (HR) was
also calculated from the blood pressure tracing.
Perfused rat heart preparations
Rat hearts were mounted on the experimental setup and
perfused as described previously (28). The heart was rapidly
excised and placed in cold KHS. The heart was mounted on
the experimental setup within 2 min after thoracotomy and
perfused at 15 ml/min (Minipuls-3 peristaltic pump; Gilson,
Middleton, WI, USA) through the aorta with KHS, main-
tained at 37°C and aerated with 95% O2  5% CO2 to
stabilize normal pH, pO2, and pCO2. Coronary perfusion
pressure (CPP) and left ventricular pressure (LVP) were
measured with two pressure transducers (HP-1280c; Hewlett-
Packard, Palo Alto, CA, USA) connected to a Hewlett-Packard
dynograph (HP-7754A). LVP was recorded with a polyethyl-
ene catheter, with a small latex balloon on the tip (Hugo
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Sachs Elektronik, March-Hugstetten, Germany), inserted into
the left ventricular cavity through the mitral valve opening.
The volume of the balloon was adjusted to give peak left
ventricular systolic pressure (LVSP) 90  5 mmHg with left
ventricular end-diastolic pressure (LVEDP) 5–7 mmHg.
Hearts that could not achieve this level of contractile perfor-
mance (8–10%) were excluded. Left ventricular developed
pressure (LVDevP; peak LVSP  LVEDP) was also calculated.
After 15 min of equilibration, hearts were paced at 300
beats/min with an electrical stimulator (S-88; Grass Instru-
ments, Rockland, Massachusetts, USA) using two silver elec-
trodes attached to the right atrium, and a further 20 min of
perfusion was carried out (preischemic period).
Effect of angiotensin II on CPP
To assess the integrity of endothelium-dependent function, at
the beginning of each experiment the coronary vasculature
reactivity to angiotensin II was evaluated in the same hearts
subsequently subjected to ischemia-reperfusion. Angiotensin
II (1 g; Sigma-Aldrich) was injected as a bolus into the
perfusion system, and changes in CPP were recorded.
Ischemia-reperfusion in the perfused rat heart
Ischemia was induced by reducing buffer flow rate from 15 to
1 ml/min for 20 min (ischemic period). Normal flow rate (15
ml/min) was then restored, and perfusion was continued for
another 30 min (reperfusion period). Throughout the exper-
iment, a thermoregulated chamber held the heart tempera-
ture at 37°C to avoid hypothermia-induced cardioprotection.
The total duration of each experiment did not exceed 90
min, during which time the experimental preparation re-
mained stable.
Creatine kinase (CK) and lactate dehydrogenase (LDH)
assay
The effluent solution obtained from the heart during the
preischemic and reperfusion periods was collected in an
ice-cold beaker as 2.5-min samples. Each sample was used for
the determination of CK and LDH activities according to
Bergmeyer (29) and Hohorst (30), respectively. The total
activity was measured spectrophotometrically (Lambda-16;
PerkinElmer, Wellesley, MA, USA) at 37°C using specific kits,
according to the manufacturer’s instructions (Sentinel Diag-
nostic, Milan, Italy).
Determination of circulating rat EPCs
A definite consensus on the best phenotype of rat EPCs is
lacking. In this study, generic rat progenitor cells were
defined as sca-1 and Sca-1c-kit, while a more specific
population of EPCs was defined as Sca-1CD31 and deter-
mined ex vivo by direct 2-color flow cytometry. We have
previously shown that the rat Sca-1c-kit cell population is
enriched with putative rat EPCs (31). Because of the simul-
taneous expression of a stem cell marker (sca-1) and an
endothelial marker (CD31), sca-1CD31 cells can be con-
sidered the homologue of human CD34KDR cells, the
most credited EPC phenotype (32).
Peripheral blood samples were drawn from the tail vein.
After red blood cell lysis, blood cells were washed and stained
with PE-conjugated anti-mouse sca-1, FITC-conjugated anti-c-
kit, or FITC-conjugated anti-rat CD31 mAbs. The frequency
of peripheral blood cells positive for the above reagents was
determined by a 2-dimensional sidescatter-fluorescence dot-
plot analysis of the samples stained with the different re-
agents, after appropriate gating to exclude granulocytes.
Initially, we gated Sca-1 peripheral blood cells and then
examined the resulting population for dual expression of
c-kit or CD31. Data were processed using the Macintosh
CellQuest software program (BD Biosciences, Franklin Lakes,
NJ, USA). A single trained operator, who was masked to the
status of the animal, performed all flow cytometric analyses
throughout the study.
Isolation and characterization of human EPCs
Human EPCs were cultured as described previously in detail,
according to a standard protocol optimized to yield true late
EPCs (32–34). Briefly, mononuclear cells were isolated from
peripheral blood of healthy female blood donors aged 	35
yr. Cells were plated on 6-well fibronectin-coated dishes (BD
Biosciences) at a density of 6 
 106 cells/well, and grown in
endothelial growth medium (EGM; Clonetics, Baltimore,
MD, USA) supplemented with 20% FCS for 15 d. Culture
medium was changed first on d 4 and then every 2 d.
Attaching cells rapidly assumed an endothelial-like shape and
proliferated in typical endothelial colonies. Two weeks after
plating, colonies tend to disappear, leaving a confluent
cobblestone monolayer. In preliminary separated experi-
ments, cells were collected at this time point and character-
ized for binding of FITC-labeled Ulex-Lectin (Sigma-Al-
drich), uptake of DiI-acetylated LDL (Molecular Probes,
Carlsbad, CA, USA), and expression of typical endothelial
markers using immunofluorescence and/or flow cytometry.
Nuclei were stained in blue with Hoechst 33258 (Sigma-
Aldrich). The following primary antibodies were used for in
situ immunofluorescence: anti-von Willebrand Factor (Dako
Cytomation, Glostrup, Denmark), anti-KDR (Santa Cruz Bio-
technology, Santa Cruz, CA, USA) and anti-CD31 (Chemicon
International, Temecula, CA, USA). Secondary antibodies for
indirect immunofluorescence were Cy2 anti-rabbit and Cy2
anti-mouse (Chemicon). FITC-conjugated anti-human CD34,
FITC-conjugated anti-human CD31, FITC-conjugated anti-
human CD14, PE-conjugated anti-human CD45 (all from BD
Biosciences), and PE-conjugated anti-KDR (R&D Systems,
Minneapolis, MN, USA) were used for flow cytometry of
cultured cells.
Clonogenic expansion of cultured EPCs
Proliferation and clonogenic expansion of cultured human
EPCs was assessed by counting typical cell colonies at d 15
after plating. EPC colonies were identified as rounded cell
clusters of 20 cells, made up of a central core of rounded
cells surrounded by radiating spindle-shaped cells. Colony
count was performed in 10 randomly selected high-power
fields for each experiment (n3). To assess the effect of PPT
and E2 on the clonogenic expansion of cultured EPCs,
starting from d 1, the culture medium was supplemented with
100 nM PPT or 100 nM E2. These concentrations were
chosen because, in preliminary experiments in which cells
were incubated with 1–10-100 nM E2, a significant increase in
EPC colonies was found with 100 nM E2.
Adhesive capacity of culture EPCs
We evaluated in vitro the functional property of EPCs to
adhere to mature endothelium, as described previously (33,
34). For this purpose, a monolayer of human umbilical vein
endothelial cells (HUVECs; Clonetics) was prepared 48 h
before the assay by plating 2
 105 cells/cm2 at early passages.
EPCs were labeled with DiI-Ac-LDL as described above, and
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 105 cells were added to each well and incubated for 2 h
at 37°C. Nonattached cells were gently removed with PBS,
and adherent EPCs were fixed with 4% p-formaldehyde in
PBS and counted in 10 random fields. To assess the effect of
PPT and E2 on adhesion of cultured EPCs to HUVECs,
starting from d 1, the culture medium was supplemented with
100 nM PPT or 100 nM E2. These concentrations were
chosen because, in preliminary experiments in which cells
were incubated with 1–10-100 nM E2, a significant increase in
adherent EPCs was found with 100 nM E2. Then, equimolar
concentrations of PPT were chosen.
Histological specimens and immunohistochemical
examinations
Five-micrometer-thick frozen sections of the uterus were
made. Hematoxylin-and-eosin staining was performed with a
commercially available kit (BioOptica, Milan, Italy), accord-
ing to the manufacturer’s instruction. High-resolution micro-
scopic images were captured, and Adobe Photoshop pho-
toediting software (Adobe Systems, San Jose, CA, USA) was
used to reconstruct the whole uterine sections. Glands were
then counted in the whole uterine tissue. Glands were
defined as tube-like/elongated structures or rounded struc-
tures with a clearly visible epithelial lining. Immunohisto-
chemistry was performed using a monoclonal antibody di-
rected against smooth muscle -actin (Sigma Aldrich),
followed by incubation with peroxidase-labeled, rabbit anti-
mouse, secondary antibody (Dako Cytomation) to identify
the myometrial area. Using Adobe Photoshop, we measured
the area of myometrium and endometrium in the whole
section to calculate the myometrial/endometrial ratio. To
identify blood vessels, immunofluorescence was performed
using an antibody against von Willebrand Factor (Dako
Cytomation), followed by incubation with Cy2-conjugated,
goat anti-rabbit, secondary antibody (Chemicon). Adobe Pho-
toshop was used to measure the signal of Cy2-labeled vessels
of high-power fields in the whole section.
Immunofluorescence observations were carried out using a
Zeiss Axioplan epifluorescence microscope (Carl Zeiss,
Oberkochen, Germany). Optical images were acquired by a
Leica DMR microscope connected to a Leica DC300 video
camera (Leica Microsystems, Wetzlar, Germany). Each count
was repeated for 10 random sections for each sample.
RT-PCR
Uterine tissue was homogenized with a polytron (IKA T10
Ultra Turrax; IKA, Staufen, Germany), and RNA was
isolated using RNeasy Mini Kit RNa column (Qiagen,
Hilden, Germany), according to the manufacturer’s in-
structions. One microgram of RNA was used for cDNA
preparation using the MuMLV reverse transcriptase (Pro-
mega, Madison, WI, USA). Control reactions without addi-
tion of the enzyme were performed for each sample. PCR
reactions were performed using 1 l cDNA and 0.4 U of
DynaZyme DNA polymerase (Finnzymes, Espoo, Finland).
The following primers (MWG Biotech, Ebersberg, Germany) were
used to amplify the respective rat genes: C3, a-5-
CTCAGTGACCAAGTGCCAGA-3 and b-5-CTCCCACTGTTCG-
GTCTGAT 3; pS2, a-5-CCATGGAGCACAAGGTGACCTG-3 and
b-5-GGGAAGCCACAATTTATTCT-3; lactoferrin, a-5-
TGGAGCAGAGTGAGTGTTGG-3 and b-5-CCACACAATCA-
GAGCCATTG-3. Amplification products were run on 3% agarose
gel. Amplification of the housekeeping enzyme glyceraldehyde
phosphodehydrogenase (gapdh) was performed in parallel to assess
for RT-PCR efficiency. The following primers were used: a-5-
ATGACCCCTTCATTGACC-3 and b-5-TGCTTCACCACCT-
TCTTG-3. PCR reactions were performed on a PerkinElmer
Thermal Cycler 480 as follows: C3: 95°C for 5 min, then 30 cycles at
92°C for 1 min, 59°C for 1 min, 72°C for 1 min; pS2: 95°C for 5 min,
then 40 cycles at 95°C for 30 s, 60°C for 30 s, 72°C for 30 s;
lactoferrin: 94°C for 2 min, then 35 cycles at 94°C for 30 s, 62°C for
30 s, 72°C for 30 s; GAPDH: 94°C for 2 min, then 23 cycles at 94°C
for 1 min, 53°C for 1 min, 72°C for 1 min.
Western blot analysis
Uterine tissues were minced in ice-cold lysis buffer (20 mM
HEPES, pH 7.9; 5 nM MgCl2; 0.1 mM EDTA; 420 nM NaCl;
20% glycerol; 0.1% Triton 100X; 5 mM -mercaptoethanol;
0.2 mM PMSF; 10 g/ml aprotinin; and 1 g/ml leupeptin)
and homogenized with a polytron. Protein extracts were
centrifuged at 24,000 g, 4°C for 30 min. Supernatant was
collected, and protein content was determined using the
Bradford assay (Pierce Chemical, Rockford, IL, USA). Pro-
teins (10 g) were separated on a 7.5% SDS-polyacrylamide
gel and transferred to a Hybond ECL nitrocellulose mem-
brane (GE Healthcare, Uppsala, Sweden). The membrane
was incubated in blocking solution for 1 h with 5% skim milk
in TBS-Tween (20 mM Tris, pH 7.5; 150 mM NaCl; and 0.2%
Tween-20). The mouse antibody C262 (kindly provided by
Dr. Geoffrey Greene, Ben May Institute, Chicago, IL, USA)
raised against human progesterone receptors was used at
1:200 dilution at 4°C overnight in TBS-Tween. After extensive
washing, a secondary HRP-conjugated anti-mouse IgG (Chemi-
con) was applied at 1:2000 dilution in TBS-Tween for 60 min;
after extensive washing, detection was performed using the ECL
kit from GE Healthcare.
Statistical analysis
All data are presented as the means  se for n experiments.
Differences between means were tested for statistical signifi-
cance using the unpaired t test or 1-way ANOVA with Newman-
Keuls multiple test, as appropriate. From such comparisons,
differences yielding P  0.05 were judged to be significant.
RESULTS
Morphometric and hemodynamic data
At 4 wk postovariectomy, OVX rats appeared generally
healthy. As shown in Table 1, there was no significant
difference in body weight among groups. SBP in OVX 
vehicle rats was significantly higher (P	0.05) than in
intact animals. This increase in SBP caused by ovariec-
tomy was fully prevented by treatment with the ER-
selective agonist PPT, but not with the nonselective ER
TABLE 1. Body weight, mean arterial pressure, and heart rate
at the end of treatment in control and ovariectomized rats
Treatment
Body
weight (g)
Systolic blood
pressure (mmHg)
Heart rate
(beats/min)
Control 289  10 128  6 315  16
OVX  vehicle 299  6 150  5* 278  12
OVX  E2 303  13 135  6 314  15
OVX  PPT 300  9 126  4† 308  12
Data are expressed as means  se; n  5 rats/group. *P 	 0.05
vs. control; †P 	 0.05 vs. OVX  vehicle
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agonist E2. No differences in heart rate were observed
among groups.
Vasorelaxant responses to ER agonists
The functional capacity of the aortic endothelium ex
vivo, which was tested by obtaining concentration-
response curves to the physiological endothelium-de-
pendent vasodilator acetylcholine, was comparable
among groups (data not shown). We previously re-
ported that addition of E2, as well as PPT, to the organ
chamber induces a rapid vasorelaxant response in
aortic tissues from intact animals and from E2-replaced
OVX animals (13, 25). Similar experiments performed
in aortic tissues from OVX rats that had been adminis-
tered PPT or vehicle are shown in Fig. 1. The addition
of both PPT and E2 rapidly relaxed in a concentration-
dependent manner NA-precontracted aortic rings
from OVX rats that had been treated with PPT (Fig.
1A), whereas no changes in vascular tone were
observed in tissues from vehicle-treated OVX rats
(Fig. 1B). Acute responses to PPT and E2 did not
significantly differ in terms of efficacy [Emax,
28.30.8 and 26.51.6, respectively; not significant
(NS)] and potency (pD2, 10.60.4 and 10.80.6,
respectively; NS). The basal NO release after NOS
blockade by L-NAME was comparable in tissues from
vehicle- and PPT-replaced animals (Supplemental
Fig. 1A). The improvement in rapid vasorelaxation to
ER agonist was observed also in tissues from OVX
animals exposed to a higher dose of PPT (100
g/kg) compared with vehicle for 4 wk (Supplemen-
tal Fig. 1B). In the latter set of experiments, we tested
the response to acetylcholine in vessels from vehicle-
and PPT-treated OVX animals and found no significant
difference (Supplemental Fig. 1C), consistent with pre-
vious results (25). Hence, the activation of rapid signal-
ing mediated by ER agonists was restored in the aorta
of PPT-treated OVX rats.
Isolated perfused rat heart studies
Angiotensin II activity on CPP
A bolus injection of 1 g angiotensin II into the
perfusion system of hearts from control rats induced a
prompt increase in CPP, which reached a peak of 22 
4 mmHg above basal values (Fig. 2). In hearts from
OVX rats, the angiotensin II-induced CPP increase was
nearly twice as large as that measured in control hearts
(P	0.05). Such hyperresponsiveness of coronary vascu-
lature to angiotensin II, an index of vascular endothe-
lium dysfunction, was prevented in heart preparations
from E2- or PPT-treated rats (Fig. 2).
Ischemia-reperfusion in the perfused rat heart
At baseline, cardiac parameters were similar and not
significantly different in the 4 experimental groups
(Table 2). When the perfusion of electrically paced
isovolumic left heart preparations from control animals
was reduced from 15 to 1 ml/min for 20 min, LVEDP
progressively rose, indicating that an ischemic process
was occurring after the standstill (Fig. 3A). During
reperfusion, left ventricular function was impaired,
LVDevP and maximum rate of rise and fall of left
ventricular pressure (dP/dtmax) being significantly
reduced, and CPP considerably increased over baseline
(Fig. 4A–C). The hearts from OVX rats subjected to
ischemia-reperfusion showed marked worsening of
Figure 1. Acute vasorelaxation in response to estrogen receptor agonists PPT or E2. Graphs show concentration-response curves
of aortic rings isolated from ovariectomized female rats that had been administered PPT (A) or vehicle (B) for 5 d. Tissues were
precontracted with 0.1 M noradrenalin and then incubated with increasing concentrations of PPT or E2. Data are shown as
means  se (n5).
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postischemic ventricular dysfunction. At the end of
reperfusion, the area under the LVEDP-time curve was
1.7-fold higher (P	0.01) than that obtained in hearts
from controls (Fig. 3B). Consequently, LVDevP (Fig.
4A) and dP/dtmax (Fig. 4B) were further depressed,
with minimal recovery of myocardial contractility.
Treatment of OVX animals with E2 and PPT induced
myocardial protection against mechanical changes due
to ischemia-reperfusion. The characteristic ventricular
contracture observed during the 20 min of ischemia was
reduced, fostering recovery of LVDevP anddP/dtmax on
reperfusion (Fig. 4A, B). In line with the improvement of
postischemic ventricular dysfunction, E2 and PPT signifi-
cantly reduced the elevated CPP during reperfusion mea-
sured in OVX  vehicle rats (Fig. 4C).
CK and LDH activity in heart perfusates
During reperfusion, activity of CK and LDH, two bio-
markers of myocardial damage, in the heart perfusates
from control rats were 4.3- and 6.6-fold higher than
those found in the preischemic period, respectively
(Fig. 4D, E). The increased severity of postischemic
ventricular dysfunction caused by ovariectomy was as-
sociated with a marked increase in CK and LDH
activities in heart effluents. During reperfusion, CK and
LDH release rates from heart preparations of OVX 
vehicle rats were nearly twice as high as in control
animals. Treatment with E2 or PPT significantly re-
duced the amount of CK and LDH compared with
OVX  vehicle rats (Fig. 4D, E).
Circulating EPC levels
EPCs have been identified as circulating precursors for
adult neovasculogenesis and vascular homeostasis and are
mobilized to the peripheral blood on many stimuli,
including vascular damage and tissue ischemia (24, 35).
We assessed the impact of ovariectomy and subsequent
Figure 2. Changes in CPP induced by angiotensin II injected
into perfused rat heart preparations during the preischemic
period. Hearts were obtained from intact (control) and OVX
rats treated with vehicle, E2, or PPT for 5 d. Values are
expressed as means  se (n5). *P 	 0.05 vs. control.
TABLE 2. Baseline cardiac parameters in isolated perfused hearts from control and OVX rats
Treatment CPP (mmHg) LVEDP (mmHg) LVDevP (mmHg) dP/dtmax (mmHg/s) dP/dtmax (mmHg/s)
Control 62.1  4.4 4.7  0.7 97.8  6.1 3070  252 2275  171
OVX  vehicle 68.3  4.7 6.0  0.8 88.9  5.0 2815  221 2050  155
OVX  E2 63.7  5.2 5.2  0.4 93.5  6.2 2916  178 2107  202
OVX  PPT 61.3  5.0 4.8  0.6 98.4  5.2 2985  213 2216  181
Values are expressed as means  se; n  5 rats/group. Cardiac parameters were evaluated immediately before ischemia. CPP, coronary
perfusion pressure; LVEDP, left ventricular end-diastolic pressure; LVDevP, left ventricular developed pressure; dP/dtmax, maximum rate of
rise and fall of left ventricular pressure.
Figure 3. A) Time course of LVEDP in perfused heart prepara-
tions subjected to ischemia-reperfusion from intact (control)
and OVX rats treated with vehicle, E2 or PPT for 5 d. B) Area
under the curve (AUC) related to LVEDP curves. All data are
shown as means  se (n 5). *P 	 0.01 vs. control; #P 	 0.05,
##P 	 0.001 vs. OVX  vehicle; §P 	 0.05 vs. OVX  E2.
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pharmacological treatment on progenitor cell release
after ischemia by measuring sca-1, sca-1c-kit, and
sca-1CD31 cells in the different groups. While sca-1
and sca-1c-kit cells are to be considered mainly hema-
topoietic, sca-1CD31 cells are the rat homologue of
human CD34KDR endothelial progenitors. Ovariec-
tomy tended to reduce EPCs, being the change significant
for sca-1 CD31 EPCs, whereas 5-d treatment with E2
and even more so with PPT significantly raised EPC
counts above control levels across the board (Fig. 5).
Effects of ER agonists on isolated human EPC function
The relevance of the above findings to the human
setting was tested in human EPCs, which were isolated
according to a validated protocol (33). The genuine
phenotype of these cells is based on lectin binding,
AcLDL uptake, and expression of typical endothelial
and stemness surface markers (Fig. 6A, B), consistent
with previous studies (33, 34). Both EPC colony forma-
tion 15 d after plating and the adhesive properties of
EPCs to a mature endothelial layer were significantly
enhanced by supplementation with E2 or PPT in cul-
ture (Fig. 6C).
Differential effects of E2 and PPT on uterine
morphology
As expected, uterus weight decreased in OVX vs. intact
animals (n5; P	0.001; Fig. 7A). Administration to
Figure 4. Multiple endpoints of ischemia-reperfusion injury are restored by E2 or PPT treatment. Recovery of LVDevP (A),
dP/dtmax (B), CPP reperfusion (C), CK (D), and LDH (E) activities in perfused heart preparations subjected to ischemia-
reperfusion from intact (control) and OVX rats treated with vehicle, E2, or PPT. LVDevP,dP/dtmax, and CPP were calculated
at the end of 30-min reperfusion and expressed as percentage of preischemic values. CK and LDH were measured during the
30-min reperfusion and expressed as increase over preischemic values (CK, 0.040.02 U/min; LDH, 0.090.02 U/min); n 
5. *P 	 0.05, **P 	 0.01 vs. control; #P 	 0.05, ##P 	 0.01, ###P 	 0.001 vs. OVX  vehicle.
Figure 5. Gating strategy used to enumerate total sca-1, total c-kit and sca-1 c-kit, and sca-1 CD31 cells by flow cytometry in
peripheral blood of intact (basal) and OVX rats treated with vehicle, PPT, or E2. sca-1 CD31 cells significantly decreased after
ovariectomy, whereas treatment with E2 and even more so PPT increased all cell types. n 5. *P	 0.05 vs. basal; †P	 0.05 vs. OVX.
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OVX rats of E2, but not of an equimolar PPT dose, for
5 d restored uterine weight (OVXE2, P	0.001 vs.
OVXvehicle; OVXPPT, NS; n5). We next investi-
gated in more detail the effect of the two ER agonists
on uterine morphology in OVX rats. Compared with
tissues from vehicle-treated animals, E2 but not PPT
treatment increased the myometrium to endometrium
thickness ratio, as shown by specific smooth muscle
-actin immunostaining (Fig. 7B). Furthermore, E2 but
not PPT treatment sharply reduced gland density, as
measured by hematoxylin-and-eosin staining, as a likely
reflection of the changed myometrial/endometrial ra-
tio. By contrast, vessel density was significantly in-
creased following treatment with both ER agonists as
measured by von Willebrand factor (vWF) immuno-
staining (Fig. 7B). The lack of significant effects on
uterine morphology other than those on vessel density
was confirmed in tissues from OVX animals exposed to
Figure 6. Characterization of cultured human EPCs and response to ER agonists. A) Immunofluorescence for lectin, acLDL,
CD31, vWF, and KDR. B) Expression of CD34, CD31, KDR, CD45, and CD14 by flow cytometry. C) Colony formation and
adhesion to a HUVEC monolayer in response to 100 nM E2 or PPT. *P 	 0.05 vs. control (CTRL).
Figure 7. A) Uterine weight from sham-operated
(control) and OVX rats treated with vehicle, E2, or
PPT for 5 d. *P 	 0.001 vs. sham-operated; #P 	
0.001 vs. OVXvehicle. B) Hematoxylin-and-eosin
(H&E) staining of uterine tissues from OVX rats
treated with vehicle, PPT or E2. To identify the
myometrial area, immunohistochemistry against
smooth muscle -actin was performed. Glands
were defined as structures with clearly visible epithelium and counted. Blood vessels were identified by immunofluorescence
using an antibody against von Willebrand factor (vWF). Images are representative sections. *P 	 0.05 vs. vehicle.
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an higher dose of PPT (100 g/kg) for 4 wk compared
with vehicle (Supplemental Fig. 2). Finally, the expres-
sion of genes known to be positively regulated by
estrogens was assessed in the uterus of OVX rats. In
contrast to E2, treatment with PPT had no effect on the
mRNA levels of complement component C3, pS2, and
lactoferrin (Fig. 8A). The same pattern could be shown
for the expression of progesterone receptors A and B at
the protein level (Fig. 8B).
DISCUSSION
The major finding of this study is that the ER-selective
agonist PPT, when administered to OVX rats, restored
endothelial function and afforded protection from
ischemia-reperfusion injury along with increased circu-
lating EPCs in the absence of uterotrophic action. To
the best of our knowledge, this is the first demonstra-
tion of cardiovascular as opposed to uterine selectivity
of ER-selective agonists in vivo and represents a clear
advance over selectivity studies in vitro (36). Conversely,
known nonselective hormonal agents, such as mamma-
lian estrogens, behave as full agonists on both ER
isoforms, thereby inducing adverse effects in classic
target tissues such as the uterus (16).
The endothelium is recognized as a biologically
active dynamic organ involved in a number of patho-
physiological processes. Herein, we show that PPT
administration restored endothelial function, as mea-
sured by acute vasorelaxant response to E2/PPT and
hyperresponsiveness to angiotensin II, and provided
cardioprotection from ischemia-reperfusion injury. Al-
though both effects have been reported to occur in
response to ER activation in separate studies (13, 19,
22), the present study depicts an integrated view of the
endothelium as a primary target of PPT action. As the
basal NO production was unaffected (Supplemental
Fig. 1A), PPT replacement likely improved endothelial
function by enhancing eNOS phosphorylation and
activation. Beyond the disruption of the ER/eNOS
signaling network (25), the present findings bring to
light additional manifestations of loss of cardiovascular
function subsequent to endogenous steroid hormone
deprivation in rats, including hypertension, increased
biomarkers of myocardial damage, and slower recovery
from ischemia. Notably, all of these events were pre-
vented by treatment with the selective ER agonist.
While the observed protection may arise from reduced
inflammatory response during reperfusion, as pro-
posed by some authors (19), the present findings
suggest an associated relationship between improved
endothelial function/angiogenic response to ischemia
and enhanced release of EPCs in response to PPT
treatment. Although we did not evaluate the specific
recruitment of the circulating EPCs at the cardiac site
after injury in this study, the bona fide integration of
labeled EPCs into blood vessels after ischemia-reperfu-
sion (31), and the beneficial effects of E2 treatment on
EPCs (34, 37) are well established. Thus, ER-mediated
enhancement of EPC function may be a unifying
mechanism underlying the widespread impact of PPT
on the serious cardiovascular dysfunction associated
with hypoestrogenicity. It is also conceivable that selec-
tive ER activation bypasses the concomitant activation
of ER by E2, which can antagonize the actions of ER
(38). This would be consistent with the superior activity
on specific cardiovascular parameters, such as LVEDP
(Fig. 3B), EPC counts (Fig. 5) and SBP (Table 1),
shown by PPT with respect to E2 in the present study.
The latter effect could be due to an effect of ER
activation in the central nervous system.
The potential relevance of the present findings to the
human setting is supported by increased in vitro adhe-
sion and proliferation of human EPCs in response to
PPT treatment. Thus, the ER-selective agonist shares
the ability of E2 to promote generation and adhesion of
EPCs, as demonstrated in a recent study using analo-
gous EPC isolation and culture conditions (34). Hu-
man EPCs express both ER isoforms, and the selective
ER antagonist methyl-piperidinethoxyphenol-pyratole
(MPP) was shown to prevent E2 action. This is consis-
tent with our results, although a role for ER in EPC
regulation cannot be ruled out (37). Further transla-
tion of the present findings to human settings remains
to be performed.
Uterus weight gain is regarded as a bioassay for ER
selectivity and target engagement. Although ligands
with preferential binding affinity for ER have shown
some vasculoprotective effects in the absence of uterus
stimulation (39, 40), our study shows that widespread
protective cardiovascular responses to ER activation
following PPT treatment in vivo also occurred in the
absence of uterotrophic response. In previous studies,
PPT doses of 1 or 2 mg/kg were associated with
Figure 8. Expression level of estrogen target genes in the
uterus. A) mRNA levels for complement 3 (C3), pS2 and
lactoferrin (LF) genes were analyzed by endpoint PCR on
uterine tissue collected from ovariectomized animals treated
for 5 d with vehicle (ctrl), E2, or PPT. PCR amplification
products were run on agarose gel using 2 animals/experi-
mental group. GAPDH gene was analyzed as control.
B) Western blot analysis of progesterone receptors in uterine
protein extracts from ovariectomized animals treated for 5 d
with vehicle, E2, or PPT. Detection of -actin was performed
as a loading control.
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uterotrophic effects (18, 41). By contrast, we adminis-
tered 16.7 g PPT/rat (67 g/kg) in Silastic capsules
implanted subcutaneously for 5 d in parallel with an
equimolar dose of E2 known to be both uterotrophic
and vasculoprotective (13, 25). On the basis of pub-
lished data (18, 42), this treatment regimen is expected
to yield plasma levels of PPT and E2 in the nanomolar
range. The mechanisms underlying the uterus-sparing
action of PPT as opposed to E2 may include differential
regulation of coactivator activity (18, 23), potency sep-
aration between different estrogenic endpoints in vivo,
and favorable pharmacokinetics featuring preferential
targeting of the vascular tree, as confirmed by the
comparable effects of PPT and E2 on uterine vessel
density (Fig. 7). Remarkably, PPT elicited no significant
effects on uterine gland density and the myometrial-to-
endometrial ratio, nor affected the expression profile
of classical target genes, consistent with the compart-
mentalization of uterine effects of ER ligands in OVX
rats (43). Because PPT could still affect vascular func-
tion without a uterotrophic effect when administered at
a higher dose (100 g/kg) for longer time (4 wk), as
shown in Supplemental Figs. 1 and 2, the therapeutic
window might be of clinical relevance.
In summary, our study shows that selective ER activa-
tion by PPT recapitulates a wide range of beneficial effects
of E2 treatment on the heart and vasculature in the
absence of untoward uterotrophic action in estrogen-
deprived rats. Whether this scenario applies to postmeno-
pausal women is worth further investigation.
This study was funded by grants from Milan University,
Padua University, the Heart Repair consortium (http://
www.heartrepair.eu), and the Italian Ministry of University
and Research (PRIN grant 2006065483_003).
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